Bristol-Myers Squibb is trading near the top of its 52-week range with firm upward price momentum over the past 3–6 months and multiple bullish technical signals, while momentum indicators approach overbought territory. Fundamentally, the company combines high margins, rising earnings, and strong free cash flow generation with elevated leverage and a recent decline in operating cash flow growth. Valuation appears moderate relative to cash generation, supported by a near-4% dividend yield and double-digit free cash flow yield, while short interest remains low despite a high short-volume share of daily trading.